Infrequent occurrence of mutations in the PH domain of LNK in patients with JAK2 mutation-negative ‘idiopathic’ erythrocytosis

Míreanna Comhchosúla

• JAK2V617F mutational status and allele burden have little influence on clinical phenotype and prognosis in patients with post-polycythemia vera and post-essential thrombocythemia myelofibrosis
  le: Guglielmelli, Paola, et al.
  Foilsithe: (2009)
• The JAK2V617 mutation induces constitutive activation and agonist hypersensitivity in basophils from patients with polycythemia vera
  le: Pieri, Lisa, et al.
  Foilsithe: (2009)
• JAK2 Allele Burden in the Myeloproliferative Neoplasms: Effects on Phenotype, Prognosis and Change with Treatment
  le: Vannucchi, Alessandro M., et al.
  Foilsithe: (2011)
• Mutation landscape in patients with myelofibrosis receiving ruxolitinib or hydroxyurea
  le: Pacilli, Annalisa, et al.
  Foilsithe: (2018)
• Hydroxyurea does not appreciably reduce JAK2 V617F allele burden in patients with polycythemia vera or essential thrombocythemia
  le: Antonioli, Elisabetta, et al.
  Foilsithe: (2010)